Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$10.14+6.7%$10.28$8.56▼$14.76$55.46M0.272,162 shs2,812 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor+4.05%+1.40%-4.11%-2.41%+7.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$10.14+6.7%$10.28$8.56▼$14.76$55.46M0.272,162 shs2,812 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor+4.05%+1.40%-4.11%-2.41%+7.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXRDaxor 2.50Moderate BuyN/AN/ACurrent Analyst Ratings BreakdownLatest ODX and DXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2026DXRDaxor Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXRDaxor$10.30M5.75N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXRDaxorN/AN/AN/AN/AN/AN/AN/AN/A8/20/2026 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDXRDaxor$0.030.30%N/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXRDaxor1.34%Insider OwnershipCompanyInsider OwnershipDXRDaxor51.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXRDaxor375.84 million2.83 millionNot OptionableODX and DXR HeadlinesRecent News About These CompaniesDaxor (NASDAQ:DXR) Trading Up 6.7% - Here's Why4 hours ago | americanbankingnews.comDaxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume MonitorJune 2, 2026 | globenewswire.comDaxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume AnalysisApril 28, 2026 | markets.businessinsider.comDaxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume AnalysisApril 28, 2026 | globenewswire.comDaxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology CenterApril 8, 2026 | globenewswire.comDaxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026March 26, 2026 | finance.yahoo.comDaxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026March 26, 2026 | globenewswire.comDaxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced ReadmissionsMarch 17, 2026 | globenewswire.comDaxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks TranscriptMarch 10, 2026 | seekingalpha.comDaxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care CongressMarch 10, 2026 | globenewswire.comDaxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026March 9, 2026 | globenewswire.comDaxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per ShareMarch 3, 2026 | globenewswire.comDaxor Scales Outpatient Presence; Launches BVA Diagnostic Program in TennesseeFebruary 24, 2026 | globenewswire.comDaxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic BusinessFebruary 10, 2026 | markets.businessinsider.comDaxor Corporation Announces $9 Million Registered Direct OfferingJanuary 23, 2026 | globenewswire.comDaxor Releases Updated Investor Presentation to Public MarketsJanuary 23, 2026 | tipranks.comWhy Daxor Corporation’s (DXR) Stock Is Up 6.47%January 7, 2026 | aaii.comAWhy Daxor Corporation’s (DXR) Stock Is Down 8.11%January 5, 2026 | aaii.comADaxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA AnalyzerNovember 25, 2025 | globenewswire.comWhy Daxor Corporation’s (DXR) Stock Is Down 9.65%November 10, 2025 | aaii.comAMedia Sentiment Over TimeODX and DXR Company DescriptionsDaxor NASDAQ:DXR$10.14 +0.64 (+6.74%) As of 06/23/2026 03:27 PM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
